Table 4 Univariable and multivariable logistic regression analysis of risk factors potentially associated with short-term efficacy in EGFR-mutated lung adenocarcinoma patients with brain metastases

Gender (Male vs. Female)

0.733

Age (≥ 60 vs.<60)

0.185

Smoker (Yes vs.No)

0.291

KPS (< 80 vs.≥80)

0.022

0.016

0.402

0.192

0.843

Location (Left lung vs.Right)

0.956

EGFR mutation type (common vs. uncommon)

0.027

0.029

5.155

1.184

22.455

Number of BMs (≤ 5 vs.>5)

0.108

Volume of BMs

0.216

Location of BMs (Only in the hemispheres of the brain vs. Exists in other location)

0.438

Symptoms of BM (Yes vs.No)

0.084

T categories of TNM (1 vs.>1)

0.825

N categories of TNM (< 3 vs.≥3)

0.287

Hepatic metastases (Yes vs.No)

0.750

Bone metastases (Yes vs.No)

0.158

Pleural metastasis (Yes vs.No)

0.357

Adrenal metastasis (Yes vs.No)

0.052

Combined with chemotherapy or antiangiogenic therapy (Yes vs.No)

0.927

First-line therapy (Yes vs.No)

0.000

0.000

0.147

0.073

0.295